Quarry LP Takes Position in Annexon, Inc. (NASDAQ:ANNX)

Quarry LP bought a new stake in Annexon, Inc. (NASDAQ:ANNX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $118,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Parkman Healthcare Partners LLC boosted its holdings in shares of Annexon by 0.5% in the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after acquiring an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Annexon by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock valued at $945,000 after acquiring an additional 2,450 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Annexon by 10.7% in the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after acquiring an additional 3,355 shares in the last quarter. Allegheny Financial Group LTD boosted its holdings in shares of Annexon by 16.1% in the second quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company’s stock valued at $123,000 after acquiring an additional 3,500 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in Annexon by 11.8% during the third quarter. MetLife Investment Management LLC now owns 55,212 shares of the company’s stock worth $327,000 after buying an additional 5,814 shares in the last quarter.

Annexon Trading Up 0.6 %

Shares of ANNX opened at $5.10 on Friday. The stock has a market cap of $543.63 million, a P/E ratio of -4.86 and a beta of 1.10. The company has a 50-day moving average of $6.50 and a two-hundred day moving average of $5.97. Annexon, Inc. has a 12-month low of $2.27 and a 12-month high of $8.40.

Analysts Set New Price Targets

A number of analysts recently commented on ANNX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $15.80.

Insiders Place Their Bets

In other news, EVP Ted Yednock sold 4,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $7.10, for a total value of $31,950.00. Following the completion of the transaction, the executive vice president now owns 71,365 shares of the company’s stock, valued at $506,691.50. The trade was a 5.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 12.67% of the stock is currently owned by company insiders.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.